The order this company entered each market — oldest to newest
GC Pharma applies for Hunterase ICV approval in Peru
GC Green Cross presents immunoglobulin thrombosis research at ISTH 2025
Sign up to see the full signal feed
How 녹십자홀딩스's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
녹십자홀딩스You | 0 | 0 | 0% | 0 | 12 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No tracked technology yet
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
GC Green Cross announced preclinical results for its LNP platform, showing improved tolerability and potential for long-term administration in rare diseases.
Chong Kun Dang ranked first in consumer interest among major Korean pharmaceutical companies in July-August, followed by Daewoong Pharmaceutical and GC Green Cross.
Chong Kun Dang ranked first in brand trust index among pharmaceutical companies in July-August, followed by GC Green Cross and Dong-A Pharmaceutical.
Be the first to find verified contacts at 녹십자홀딩스
Quick answers about 녹십자홀딩스's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.